Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Monalizumab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innate Pharma: Monalizumab Data From NeoCOAST-2 Presented At WCLC 2024
    Innate Pharma: Monalizumab Data From NeoCOAST-2 Presented At WCLC 2024

    09 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240908660298/en

    BUSINESSWIRE
    09 Sep 2024
    Share Share
    Innate to Present Lacutamab PTCL Phase 1b Design & ANKET Platform at ESMO 2022
    Innate to Present Lacutamab PTCL Phase 1b Design & ANKET Platform at ESMO 2022

    05 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220904005030/en

    BUSINESSWIRE
    05 Sep 2022
    Share Share
    AstraZeneca's novel checkpoint inhibitor flunks first phase 3
    AstraZeneca's novel checkpoint inhibitor flunks first phase 3

    02 Aug 2022

    // Nick Paul Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/astrazenecas-novel-checkpoint-inhibitor-flunks-first-phase-3-denting-partners-share-price

    Nick Paul Taylor FIERCEBIOTECH
    02 Aug 2022
    Share Share
    Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
    Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

    01 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220731005041/en

    BUSINESSWIRE
    01 Aug 2022
    Share Share
    Patient Dosed in Monalizumab Phase 3 Lung Cancer Trial Triggers $50M Payment
    Patient Dosed in Monalizumab Phase 3 Lung Cancer Trial Triggers $50M Payment

    29 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220428006062/en

    BUSINESSWIRE
    29 Apr 2022
    Share Share
    Innate Pharma: Monalizumab + Cetuximab & Durvalumab Shows Anti-Tumor Activity
    Innate Pharma: Monalizumab + Cetuximab & Durvalumab Shows Anti-Tumor Activity

    09 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211209005158/en

    BUSINESSWIRE
    09 Dec 2021
    Share Share